Combined androgen blockade for the treatment of metastatic cancer of the prostate

By Schellhammer P.F.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 622-628

Elsevier

Access to resources Recommend Favorite

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy - a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

By van der Kwast T.H.   Tetu B.   Candas B.   Gomez J.-L.   Cusan L.   Labrie F.  

Urology, Vol. 53, Iss. 3, 1999-03 ,pp. : 523-529

Elsevier

Access to resources Recommend Favorite

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

By Labrie F.   Candas B.   Gomez J.-L.   Cusan L.  

Urology, Vol. 60, Iss. 1, 2002-07 ,pp. : 115-119

Elsevier

Access to resources Recommend Favorite

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial

By Schellhammer P.F.   Sharifi R.   Block N.L.   Soloway M.S.   Venner P.M.   Patterson A.L.   Sarosdy M.F.   Vogelzang N.J.   Schellenger J.J.   Kolvenbag G.J.C.M.  

Urology, Vol. 50, Iss. 3, 1997-09 ,pp. : 330-336

Elsevier

Access to resources Recommend Favorite

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review 2

By Schmitt B.   Wilt T.J.   Schellhammer P.F.   DeMasi V.   Sartor O.   Crawford E.D.   Bennett C.L.  

Urology, Vol. 57, Iss. 4, 2001-04 ,pp. : 727-732

Elsevier

Access to resources Recommend Favorite